Article ; Online: A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia.
Modern rheumatology case reports
2023 Volume 8, Issue 1, Page(s) 1–4
Abstract: We experienced a case of rheumatoid arthritis and JAK2V617F mutation-positive essential thrombocythemia treated with baricitinib. The patient was a 72-year-old male. He was diagnosed with rheumatoid arthritis at a local clinic in April 2018. Methotrexate ...
| Abstract | We experienced a case of rheumatoid arthritis and JAK2V617F mutation-positive essential thrombocythemia treated with baricitinib. The patient was a 72-year-old male. He was diagnosed with rheumatoid arthritis at a local clinic in April 2018. Methotrexate (MTX) was started and the dose was increased to 16 mg/week. In October of the same year, anaemia was observed and MTX was reduced, but anaemia progressed. Blood tests showed pancytopenia, and he was referred to Rheumatology on suspicion of drug-induced pancytopenia. Pancytopenia improved with discontinuation of MTX and administration of folic acid. His platelet count was markedly increased to 1,400,000/μl at one point, decreased to 400,000/μl, and then gradually increased to 700,000-1,000,000/μl. Despite taking an antiplatelet drug, he developed cerebral infarction in June 2019. The JAK2V617F mutation was noted, and he was diagnosed with essential thrombocythemia. Hydroxycarbamide was started, but the effect was insufficient. Baricitinib, a JAK1/2 inhibitor indicated for rheumatoid arthritis, was started in August with the expectation that it would also be effective for essential thrombocythemia. The platelet count decreased to ∼400,000-600,000 cells/μl, and a decrease in the C-reactive protein level and the improvement of arthritis were noted. We report this case because it is considered to be a valuable case, suggesting that baricitinib may be effective for essential thrombocythemia. |
|---|---|
| MeSH term(s) | Male ; Humans ; Aged ; Antirheumatic Agents/therapeutic use ; Thrombocythemia, Essential/complications ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/drug therapy ; Pancytopenia/drug therapy ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Methotrexate/therapeutic use ; Anemia/drug therapy |
| Chemical Substances | Antirheumatic Agents ; baricitinib (ISP4442I3Y) ; Methotrexate (YL5FZ2Y5U1) |
| Language | English |
| Publishing date | 2023-05-26 |
| Publishing country | England |
| Document type | Case Reports ; Journal Article |
| ISSN | 2472-5625 |
| ISSN (online) | 2472-5625 |
| DOI | 10.1093/mrcr/rxad012 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.